Fierce Biotech June 10, 2024
Moderna’s combo flu and COVID-19 vaccine zipped through a late-stage trial this winter, and the results are showing a higher immune response than licensed comparators—including the famed biotech’s own Spikevax.
MRNA-1083 is made up of Moderna’s flu shot mRNA-1010 and the next-generation COVID-19 vaccine mRNA-1283. Both components have individually shown efficacy in late-stage trials.
But together, Moderna hopes to create a product that can reduce the burden on patients and caregivers each season.
“One of the things that we learned from the COVID experience is that there is a certain, let’s say, fatigue to COVID-19 vaccine, and the difference between the vaccine coverage rates of influenza and COVID is quite substantial,” Francesca Ceddia, M.D., Moderna’s chief medical affairs officer, said...
Today's Sponsors
Today's Sponsor